USP52 inhibits cell ferroptosis via Hippo–YAP pathway and blocks immunotherapy in colorectal cancer
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110725 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Jingkai Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China; Hubei Provincial Clinical Research Center for Intestinal and Col…. Hauptthemen laut MEDLINE: Ferroptosis, Colorectal Neoplasms, Protein Serine-Threonine Kinases, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wuhan University, National Natural Science Foundation of China, Zhongnan Hospital of Wuhan University.
Abstract (Originalsprache)
Colorectal cancer (CRC) is one of the most prevalent malignancies in humans. Understanding its molecular mechanisms to guide clinical management is crucial. Ferroptosis represents a novel form of regulated cell death that is characterized by highly iron-dependent lipid peroxidation. Despite growing interest, the roles and vulnerabilities determining ferroptosis sensitivity in CRC remain unclear. In this study, we identified ubiquitin-specific peptidase 52 (USP52) as a specific deubiquitinating enzyme of Yes-associated protein (YAP) in CRC, which could stabilize YAP by removing the K11-linked ubiquitin chains. USP52 knockdown decreased the expression of YAP protein and its target gene (CTGF, CYR61). Through a series of comprehensive in vivo and in vitro experiments, we proved that USP52 promoted CRC cell proliferation, migration, and invasion and attenuated the sensitivity of CRC cells to ferroptosis. Notably, USP52 inhibition retarded tumor growth and enhanced CD8+ T-cell infiltration, which potentiated tumor response to anti-programmed death-ligand-1 immunotherapy in vivo. In general, our research uncovered that USP52 suppressed ferroptosis through the Hippo-YAP signaling and highlighted targeting USP52 as a potential therapeutic strategy to boost ferroptosis for enhancing cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China; Hubei Provincial Clinical Research Center for Intestinal and Colorectal Diseases, Wuhan, China; Hubei Key Laboratory of Intestinal and…
- Department of Anesthesiology, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Office of Academic Research, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Department of Pharmacy, Wuhan Seventh Hospital, Wuhan, China.
- Department of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Förderung
- Wuhan University
- National Natural Science Foundation of China
- Zhongnan Hospital of Wuhan University
Zitieren
APA
Zhou, J., Nie, H., Liu, C., Ding, L., Zheng, T., Du, L., Yu, Y., Hong, Y., Yang, C., Zhao, Q., Zhang, M., Wang, H., & Wang, F. (2025). USP52 inhibits cell ferroptosis via Hippo–YAP pathway and blocks immunotherapy in colorectal cancer. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110725
Vancouver
Zhou J, Nie H, Liu C, Ding L, Zheng T, Du L, et al. USP52 inhibits cell ferroptosis via Hippo–YAP pathway and blocks immunotherapy in colorectal cancer. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110725
BibTeX
@article{Zhou2025,
author = {Zhou, Jingkai and Nie, Haihang and Liu, Chenhui and Ding, Lu and Zheng, Ting and Du, Li and Yu, Yali and Hong, Yuntian and Yang, Chao and Zhao, Qiu and Zhang, Meng and Wang, Haizhou and Wang, Fan},
title = {USP52 inhibits cell ferroptosis via Hippo–YAP pathway and blocks immunotherapy in colorectal cancer},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110725}
}
EUVIMED